

HARNES, DICKEY & PIERCE, P.L.C.

Attorneys and Counselors
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
Phone: 314-726-7500
Fax: 314-726-7501

Troy, MI • Ann Arbor, MI • Washington, D.C.

*Amend
6/6/03
40*

FAX MESSAGEDATE: *June 5, 2003*

NO. OF PAGES (INCLUDING THIS PAGE):

*45*FOR: *Examiner Solola*COMPANY: *U.S. Patent Office*FAX NO.: *9-1-703-308-7922*

PHONE:

ORIGINAL WILL FOLLOW BY:

- ☐ REGULAR MAIL
☐ OVERNIGHT MAIL
☐ COURIER
☒ WILL NOT FOLLOW

FROM:

David Gryte

Please let us know by phone or fax if you do not receive any of these pages.

COMMENTS:

*** NOTICE ***

The information contained in this telefax transmission is intended only for the individual to whom or entity to which it is addressed. It may also contain privileged, confidential, attorney work product or trade secret information which is protected by law. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering the message to the addressee, the reader is hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the address above via the U.S. Postal Service. We will reimburse you for any reasonable expense (including postage) for the return of the original message.

HARNES, DICKEY & PIERCE, P.L.C.

ATTORNEYS AND COUNSELORS
7700 BONHOMME, SUITE 400
ST. LOUIS, MISSOURI 63105

TELEPHONE (314) 726-7500
FAX (314) 726-7501

DETROIT, MICHIGAN

WASHINGTON, D.C.

David M. Gryte
(314) 726-7508
dgryte@hdp.com

June 5, 2003

VIA FACSIMILE (703) 308-7922

Examiner Taofiq A. Solola
Commissioner For Patents
Alexandria, Virginia 22313-1450

RE: U.S. Patent Application No. 10/021,780
Title: Substituted Pyrazoles as p38 Kinase Inhibitors
Applicant: Ashok Anantanarayan et al.
Filing Date: December 7, 2001

Dear Examiner Solola:


This is a follow-up to my June 4, 2003 email response to your June 4, 2003 email.

We filed Amendment C in accordance with the recently revised 37 CFR 1.121 (Manner of Making Amendments). It is our understanding that this revised rule mandates that all amendments provide *only* a marked-up set of claims, rather than both a marked-up and clean set. Nevertheless, we are happy to accommodate your request for both marked-up and clean sets. A marked-up set of claims is shown in the attached Appendix A. A clean set is shown in the attached Appendix B.

As to the requirement for a terminal disclaimer, we will provide a terminal disclaimer (to the extent necessary) once the claims have been found to be otherwise allowable. If, in fact, the claims have been found to be otherwise allowable, please confirm this finding in writing.

Thank you for your courtesy during our recent calls and correspondence. Please let me know if you need any additional information. Again, my email address is dgryte@hdp.com.

Best regards,


David M. Gryte

attach.
DMG/